|
|
|
Featured Content |
|
|
Top Stories |
NIH Announces Positive Results for Experimental Ebola Vaccine
NIH announced positive safety results from the vaccine, VSV-ZEBOV, and found that all patients in the study experienced a strong antibody response. More... |
|
Horizon Offers $1.1 Billion for Hyperion
Horizon Pharma offers to buy Hyperion Therapeutics for $1.1 billion in cash. More... |
|
|
Industry News |
GSK Announces US Vaccine R&D Center
GlaxoSmithKline announces global vaccines research and design facility to be based in Rockville, MD, USA. More... |
|
Catalent Acquires Australias Pharmapak Technologies
Catalent acquires Pharmapak Technologies, a pharmaceutical packaging company based in New South Wales, Australia. More... |
|
USP Establishes Elemental Impurities Implementation Dates
USP announces an implementation date of Jan. 1, 2018 for General Chapters <232> Elemental Impurities—Limits and <2232> Elemental Contaminants in Dietary Supplements. More... |
|
Merck Joins CAR T-cell Market with $941 Million Intrexon Alliance
Merck Serono announces that it will work with Intrexon to develop a cancer therapy using chimeric antigen receptor T-cells. More... |
|
Stronger Pipelines and Approvals Drive Small-Molecule APIs and CMO Opportunities
Statistics presented in a March webinar suggest a strong, but highly fragmented, small-molecule API market. More... |
|
Novartis Inks $250 Million Alliance with Aduro
Novartis announced that it entered into a multiyear alliance with Aduro Biotech to develop cancer immunotherapies, offering up to $250 million in upfront payments and equity investments. More... |
|
Hamburg Era Ends at FDA
Commissioner Margaret Hamburg discusses globalization challenges and the need for investment in regulatory science during her last weeks at the agency. More... |
|
FDA Denies Amgen's Certification Petition in Biosimilar Patent Dance
Biosimilar applicants will not be required to hand over their biosimilar applications and manufacturing dossiers to innovator companies, determines FDA. More... |
|
|
|
DIOSNA Dierks & Söhne GmbH
DIOSNA CCS 10 in Isolator The advantages of the compact design and ease of use of Diosna's pharmaceutical mixer P1-6 and fluid bed processor Midilab XP are the main reasons for integrating them in isolators when granulation equipment for high potent products at laboratory scale (approx.. 0.1 kg - 5 kg) is needed.
Read more
|
 |
|
|
|
|
|
Reference Library |
Pharmaceutical Technology Solid Dosage Combo
Increase your knowledge of solid dosage technology and solid dose tablet manufacturing processes. These comprehensive pharmacology reference guides cover a variety of solid-dosage form principles such as oral solid-dosage forms, powders, mixing and blending, excipients, tableting, and coating. Drug delivery system manufacturing professionals can use the solid dosage manufacturing books to stay current with compressed tablet manufacturing processes, solid dosage processing equipment, tablet-pressing processes, and pharmaceutical industry trends in oral solid dosage manufacturing and solid dosage form development. ... Click here
|
|
Contact Us |
Click here to contact editorial.
Click here to contact sales. |
|